medigraphic.com
ISSN 1561-3046 (Electronic)

2021, Number 2

<< Back Next >>

Rev Cub Med Mil 2021; 50 (2)

Cardiac biomarkers of atherothrombosis and their implication in estimating the risk of cardiovascular disease

Rodríguez PJM

Language: Spanish
References: 31
Page:
PDF size: 218.45 Kb.


ABSTRACT

Introduction: Innovative cardiovascular risk estimation strategies that use cardiac biomarkers of atherothrombosis have been shown to be superior in cardiovascular risk stratification that those predictions based exclusively on the evaluation of traditional risk factors in isolation. A bibliographic review, analysis and categorization of different articles was performed in the databases Cumed, Lilacs, Scielo, Medline, the key terms for the search were: "homocysteine", "lipoprotein (a)" and "cardiovascular risk", in Spanish, English and Portuguese languages. Original review articles were considered, including systematic reviews and published meta-analyzes after 2000.
Objective: To analyze some of the cardiac biomarkers of atherothrombosis that may be involved in the development of atherosclerotic cardiovascular disease and its thrombotic complications.
Development: Accumulated evidence supports that cardiac biomarkers such as: hyperhomocysteinemia, hyperlipoproteinemia (a), increased plasma fibrinogen levels, coagulant factor VII, Plasminogen Tissue Activator Inhibitor type 1 and C-reactive protein are tools of Very useful for stratifying cardiovascular risk in those individuals with intermediate risk, or with unusual or undefined risk, essentially in the field of primary and secondary prevention of cardiovascular disease.
Conclusions: The identification of additional predictive emergent atherothrombosis biomarkers is crucial for a more effective prevention and therapy of atherosclerotic cardiovascular disease.


REFERENCES

  1. Toros Xavier H, Castellanos R, Fernández-Britto JE. Fibrinógeno y riesgo trombótico cardiovascular: algunas reflexiones. Rev Cubana Invest Biomed. 2005[acceso: 19/01/2020];24(3):[aprox. 15p.]. Disponible en: Disponible en: http://scielo.sld.cu/pdf/ibi/v24n3/ibi04305.pdf

  2. Vega Abascal J, Guimará Mosqueda M, Vega Abascal L. Riesgo cardiovascular, una herramienta útil para la prevención de las enfermedades cardiovasculares. Rev Cubana Med Gen Integr. 2011 [acceso: 19/01/2020]; 27(1):91-97. Disponible en: Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-21252011000100010

  3. Tamayo Salazar E, Sánchez Soto JM, Estévez Ramos RA, Basset Machado I. Evaluación del riesgo cardiovascular mediante la aplicación de la tabla de Framingham. Rev Cubana Enfermer. 2017 [acceso: 16/01/2020]; 33(1):149-58. Disponible en: Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-03192017000100017&lng=es&nrm=iso&tlng=es

  4. de Ruijter W, Westendorp R, Assendelft WJJ, den Elzen W PJ, de Craen AJM, le Cessie S, et al. Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study. BMJ. 2009 [acceso: 11/01/2020]; 338:3083. Disponible en: Disponible en: https://www.bmj.com/content/338/bmj.a3083

  5. Pandey A, Patel KV, Vongpatanasin W, Ayers C, Berry JD, Mentz RJ, et al. Incorporation of Biomarkers Into Risk Assessment for Allocation of Antihypertensive Medication According to the 2017 ACC/AHA High Blood Pressure Guideline: A Pooled Cohort Analysis. Circulation. 2019[acceso: 08/01/2020]; 17;140(25):2076-2088. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/31707797

  6. Leite LO, Faria Costa PR, Pereira da Conceiçao-Machado ME, Dias Pitangueira JC. Homocisteína y cisteína: marcadores de riesgo cardiovascular en adolescentes. Revista Adolescência e Saúde.2018[acceso: 06/01/2020]; 15(4):104-113. Disponible en: Disponible en: http://www.adolescenciaesaude.com/detalhe_artigo.asp?id=751&idioma=Espanhol

  7. Mostaza JM, Pintó X, Armario P, Masana L, Ascaso JF, Valdivielso P. Estándares SEA 2019 para el control global del riesgo cardiovascular. Clin Investig Arterioscler. 2019[acceso: 26/01/2020];31(S1):1-43. Disponible en: Disponible en: https://www.sciencedirect.com/journal/clinica-e-investigacion-en-arteriosclerosis/vol/31/suppl/S1

  8. Achiong Alemañy M, Achiong Estupiñán F, Afonso de León JA, Álvarez Escobar MC, Suárez Merino M. Riesgo cardiovascular global y edad vascular: herramientas claves en la prevención de enfermedades cardiovasculares. Rev. Med. Electrón. 2016 [acceso: 12/02/2020]; 38(2):211-26. Disponible en: Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1684-18242016000200010

  9. Ruiz Mori E, Segura Vega L, Agusti Campos R. Uso del Score de Framingham como indicador de los factores de riesgo de las enfermedades cardiovasculares en la población peruana. Revista Peruana de Cardiología. 2012[acceso: 25/02/2020]; XXXVIII(3):1-19. Disponible en: Disponible en: https://www.revespcardiol.org/contenidos/static/premio_cardio/revista-peruana-cardiologia.pdf

  10. Ruiz Mori E. Riesgo y Prevención Cardiovascular. Lima: Edición Lima; 2014.

  11. Ruiz Mori E, Ruiz M H, Guevara Gonzales L, Ortecho Arias H, Salazar Rojas R, Torres Mallma C, et al. Factores de riesgo cardiovascular en mayores de 80 años. Horiz Med. 2015[acceso: 24/02/2020]; 15(3):26-33. Disponible en: Disponible en: https://www.redalyc.org/pdf/3716/371642259005.pdf

  12. Escosa Royo L, Galache Osuna JG, Monzón Lomas F, Moreno Esteban E, Salazar González JJ, Sánchez-Rubio Lezcano J, et al. ¿es la homocisteína un factor de riesgo coronario?. Cardioaragon. 2003[acceso: 23/02/2020]; 7(1):[aprox. 15p.]. Disponible en: Disponible en: https://www.cardioaragon.com/revistas/volumen-7-numero-1/es-la-homocisteina-un-factor-de-riesgo-coronario/

  13. Woo Kwon S, Kim JY, Ju Suh Y, Hyung Lee D, Won Yoo Y, Kwon Lee B. Prognostic Value of Elevated Homocysteine Levels in Korean Patients with Coronary Artery Disease: A Propensity Score Matched Analysis. Korean Circ J. 2016 [acceso: 23/02/2020];46(2):154-160. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4805559/

  14. Edin Zylberstein D, Bengtsson C, Björkelund C, Landaas S, Sundh V, Thelle D, Lissner L. Serum Homocysteine in Relation to Mortality and Morbidity From Coronary Heart Disease. A 24-Year Follow-Up of the Population Study of Women in Gothenburg. Circulation . 2004[acceso: 13/02/2020]; 109(5):601-6. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/14769681

  15. Loukianos S R, Nikolaos K, Taxiarchoula R, Georgios P, Estela K, Maria Z. Homocysteine is an independent predictor of long-term cardiac mortality in patients with stable coronary artery disease in the era of statins. Coronary Artery Disease Journal. 2020[acceso: 05/01/2020];31(2):152-6. Disponible en: Disponible en: https://journals.lww.com/coronary-artery/Fulltext/2020/03000/Homocysteine_is_an_independent_predictor_of.8.aspx

  16. Gupta S, Gudapati R, Gaurav K, Bhise M. Emerging risk factors for cardiovascular diseases: Indian context. Indian J Endocr Metab. 2013[acceso: 03/02/2020]; 17:806-14. Disponible en: Disponible en: http://www.ijem.in/article.asp?issn=2230-8210;year=2013;volume=17;issue=5;spage=806;epage=814;aulast=Gupta

  17. Tofler GH, Massaro J, O'Donnell CJ, Wilson PWF, Vasan RS, Sutherland PA, et al . Plasminogen activator inhibitor and the risk of cardiovascular disease: The Framingham Heart Study. Thromb Res. 2016[acceso: 23/02/2020]; 140:30-35. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/26896607

  18. Santiso Ramos M, López Santiso P, Robert Companini L, Cabrera Espinosa O. Homocisteína, marcador de riesgo vascular. Revisión bibliográfica. MediCiego. 2016[acceso: 07/02/2020];22(4):[aprox. 10 p.]. Disponible en: Disponible en: http://www.revmediciego.sld.cu/index.php/mediciego/article/view/564/1065

  19. Sontakke AN, Tilak MA, Dhat VV, More UM, Shinde SA, Phalak P, et al. Prevalence of Elevated Serum Homocysteine and Serum Lipoprotein "a" in Women. Journal of Clinical and Diagnostic Research : JCDR. 2014[acceso: 23/02/2020]; 8(10):13-5. Disponible en: http://doi.org/10.7860/JCDR/2014/9607.4995

  20. Machado F, Reyes X. ¿Qué debe saber el cardiólogo clínico sobre la lipoproteína (a)? Rev. Urug. Cardiol. 2019[acceso: 23/02/2020]; 34 (3): 333-340. Disponible en: Disponible en: http://www.scielo.edu.uy/pdf/ruc/v34n3/1688-0420-ruc-34-03-260.pdf

  21. Saeedi R, Frohlich J. Lipoprotein (a), an independent cardiovascular risk marker. Clin Diabetes Endocrinol. 2016[acceso: 21/02/2020]; 2:7. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471681/

  22. Wang Z, Zhai X, Xue M, Cheng W, Hu H. Prognostic value of lipoprotein (a) level in patients with coronary artery disease: a meta-analysis. Lipids Health Dis. 2019[acceso: 23/02/2020]; 18:150. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615167/

  23. Wilson DP, Jacobson TA, Jones PH, Koschinsky ML, McNeal CJ, Nordestgaard BG, et al. Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol. 2019[acceso:23/02/2020];13(3):374-392. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/31147269

  24. Canseco-Ávila LM, Jerjes-Sánchez C, Ortiz-López R, Rojas-Martínez A, Guzmán-Ramírez D. Fibrinógeno. ¿Factor o indicador de riesgo cardiovascular? Arch. Cardiol. Méx. 2006[acceso: 23/02/2020]; 76(supl.4):158-172. Disponible en: Disponible en: https://www.medigraphic.com/pdfs/archi/ac-2006/acs064o.pdf

  25. Luc G, Bard J, Juhan-Vague I, Ferrieres J, Evans A, Amouyel P, et al. C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study. Arterioscler Thromb Vasc Biol. 2003[acceso: 22/02/2020]; 23(7):1255-61. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/12775578

  26. Ndrepepa G, Braun S, Tada T, King L, Cassese S, Fusaro M, et al. Comparative prognostic value of C-reactive protein & fibrinogen in patients with coronary artery disease. Indian J Med Res. 2014[acceso: 13/02/2020]; 140(3): 392-400. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4248386/

  27. Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG. Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke: the Edinburgh Artery Study. Circulation . 2007;115(16):2119-27. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/17404162

  28. Fibrinogen Studies Collaboration, Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA2005[acceso: 23/02/2020];294 (14):1799-1809. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/16219884

  29. Jiang P, Gao Z, Zhao W, Song Y, Tang XF, Xu JJ, et al. Relationship between fibrinogen levels and cardiovascular events in patients receiving percutaneous coronary intervention: a large single-center study. Chin Med J (Engl). 2019[acceso: 23/02/2020];132(8):914-21. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6595753/

  30. Comisión de Nuevos factores de riesgo. Revista Argentina de Cardiología. 2001 [acceso: 23/02/2020]; 69 (suplemento 1): 1-14. Disponible en: Disponible en: https://www.sac.org.ar/wp-content/uploads/2014/04/nuevosfactores.pdf

  31. Jung RG, Motazedian P, Daniel Ramírez FD, Simard T, Di Santo P, Visintini S, et al. Association between plasminogen activator inhibitor-1 and cardiovascular events: a systematic review and meta-analysis. Thromb J. 2018[acceso: 19/02/2020]; 16:12. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5987541/




2020     |     www.medigraphic.com